Roflumilast foam, 0.3%, proved to be a simplified treatment regimen with high efficacy for patients with scalp and body ...

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed.

Arcutis Biotherapeutics (ARQT) announced that the Journal of American Medical Association Dermatology published the results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE ...

Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy66.4% of individuals treated with ZORYVE foam achieved Scalp-I ...

Arcutis Biotherapeutics Inc (ARQT) reports a remarkable 196% year-over-year revenue increase, driven by strong demand for ...

supported by expected approvals for ZORYVE foam for scalp and body psoriasis in May and ZORYVE cream for atopic dermatitis in children ages two to five in October. The company sees significant ...

The company has a PDUFA action date of May 22, 2025 for ZORYVE foam 0.3% in the treatment of plaque psoriasis of the scalp and body. This article was generated with the support of AI and reviewed by ...